Efalizumab - Wikipedia, the free encyclopedia
Efalizumab (trade name Raptiva, Genentech, Merck Serono) is a medication designed to treat psoriasis. As implied by the suffix -zumab, it is a recombinant humanized monoclonal antibody.
Siplizumab - Wikipedia, the free encyclopedia
immunosuppressive: Aselizumab, Apolizumab, Cedelizumab, Certolizumab pegol, Daclizumab, Eculizumab, Efalizumab, Epratuzumab, Erlizumab, Fontolizumab, Mepolizumab, Natalizumab, ...
efalizumab - definition of efalizumab in the Medical dictionary - by ...
efalizumab, a rarely used immunosuppressant. indications This drug is used in adults 18 years of age and older to treat moderate to severe plaque psoriasis.
Efalizumab Patients: Transition, Don't Just Stop
Efalizumab is being withdrawn from the U.S. market; this page explains what dermatologist say you should know if you are treating your psoriasis with efalizumab.
efalizumab - Providence Health & Services
Efalizumab increases the risk of serious infections, including a viral infection of the brain that can lead to disability or death. This risk is higher if you have a weak immune ...
Genentech Withdraws Raptiva (Efalizumab) For Psoriasis
Genentech, the company that makes Raptiva (efalizumab) to treat psoriasis, recently announced it has begun a voluntary, phased withdrawal of the drug from the U.S. market because it ...
Raptiva Efalizumab - Information on Raptiva Afalizumab
Research Raptiva Efalizumab information, news and resources on drug recalls such as Raptiva. If you've experienced health complications while using the Raptiva drug, you may have ...
Efalizumab Withdrawn From US Market
: Efalizumab (Raptiva), used for the treatment of psoriasis, will no longer be available in the United States because of the risk for progressive multifocal leukoencephalopathy.
